132 related articles for article (PubMed ID: 15791831)
1. Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response.
Yuan Y; He Y; Wang X; Zhang H; Li D; Feng Z; Zhang G
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(6):531-4. PubMed ID: 15791831
[TBL] [Abstract][Full Text] [Related]
2. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity.
Elhag OA; Hu XJ; Wen-Ying Z; Li X; Yuan YZ; Deng LF; Liu DL; Liu YL; Hui G
Asian Pac J Cancer Prev; 2012; 13(8):4031-6. PubMed ID: 23098512
[TBL] [Abstract][Full Text] [Related]
3. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
4. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
6. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
7. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.
Li G; Wu X; Zhang F; Li X; Sun B; Yu Y; Yin A; Deng L; Yin J; Wang X
J Cancer Res Clin Oncol; 2011 Apr; 137(4):695-703. PubMed ID: 20563597
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
[TBL] [Abstract][Full Text] [Related]
9. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
He YF; Wang XH; Zhang GM; Chen HT; Zhang H; Feng ZH
Cancer Immunol Immunother; 2005 Sep; 54(9):891-7. PubMed ID: 15776283
[TBL] [Abstract][Full Text] [Related]
10. Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
[TBL] [Abstract][Full Text] [Related]
11. [Soluble PD-1 can augment anti-tumor immunity induced by HSP70-peptide complex in tumor-bearing mice].
Wang XH; Zhang GM; He YF; Zhang H; Feng ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):655-8. PubMed ID: 15555427
[TBL] [Abstract][Full Text] [Related]
12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
13. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.
He L; Zhang G; He Y; Zhu H; Zhang H; Feng Z
Anticancer Res; 2005; 25(5):3309-13. PubMed ID: 16101143
[TBL] [Abstract][Full Text] [Related]
14. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
15. Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50.
Qiu H; Liu S; Xie C; Long J; Feng Z
Anticancer Res; 2009 Dec; 29(12):5089-94. PubMed ID: 20044621
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
17. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.
Huber S; Hoffmann R; Muskens F; Voehringer D
Blood; 2010 Oct; 116(17):3311-20. PubMed ID: 20625006
[TBL] [Abstract][Full Text] [Related]
18. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Qin X; Liu C; Zhou Y; Wang G
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
[TBL] [Abstract][Full Text] [Related]
20. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
